PERBANDINGAN JUMLAH TROMBOSIT PRIMIGRAVIDA DENGAN MULTIGRAVIDA PADA KEJADIAN PREEKLAMPSIA DI RUMAH SAKIT IBNU SINA GRESIK PERIODE TAHUN 2019 – 2021

Anita Dahliana; Ummy Maisarah Rasyidah; Arya  Rizky Fernanda; Nita Damayanti

doi:10.31970/ma.v5i2.132

Anita Dahliana Faculty of Medicine, University of Surabaya
Ummy Maisarah Rasyidah Faculty of Medicine, University of Surabaya
Arya Rizky Fernanda Faculty of Medicine, University of Surabaya
Nita Damayanti Faculty of Medicine, University Alkhairaat

DOI: https://doi.org/10.31970/ma.v5i2.132

Keywords: Gravida, Primigravida, Multigravida, Preeclampsia, Platelet

Abstract

Latar belakang: Preeklampsia adalah suatu kondisi dimana ibu hamil dengan masa kehamilan lebih dari 20 minggu memiliki tanda utama hipertensi dan proteinuria. Penelitian ini bertujuan untuk menganalisis perbedaan jumlah trombosit antara primigravida dan multigravida pada kejadian preeklampsia. Metode: Penelitian ini merupakan penelitian cross-sectional. Pengumpulan data menggunakan probability sampling yaitu purposive sampling dengan 61 rekam medik ibu preeklampsia yang diambil sesuai kriteria inklusi di RS Ibnu Sina Gresik yang terdiri dari 14 primigravida dan 47 multigravida dari tahun 2019 sampai dengan 2021. Hasil: Pasien preeklampsia dengan jumlah trombosit terendah adalah 170 kelompok, terendah.000/L dan tertinggi 490.000/μL dengan rerata 282.066/μL. Pada primigravida jumlah trombosit 170.000/L dan tertinggi 342.000/L dengan rata-rata 277.857/μL, sedangkan pada kelompok multigravida memiliki jumlah trombosit terendah 173.000/μL dan tertinggi 490.000/μL dengan rata-rata 283.319/ L. Kedua kelompok dibandingkan dan hasilnya menunjukkan bahwa tidak ada perbedaan bermakna jumlah trombosit antara primigravida dan multigravida (p>0,05). Simpulan: Tidak terdapat perbedaan bermakna antara jumlah trombosit primigravida dan multigravida pada pasien preeklampsia.

Downloads

Download data is not yet available.

References

1. Nakimuli A, Nakubulwa S, Kakaire O, Osinde MO, Mbalinda SN, Kakande N, et al. The burden of maternal morbidity and mortality attributable to hypertensive disorders in pregnancy: A prospective cohort study from Uganda. BMC Pregnancy Childbirth [Internet]. 2016;16(1):1–8. Available from: http://dx.doi.org/10.1186/s12884-016-1001-1
2. Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw open. 2021 May;4(5):e218401.
3. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124(7):1094–112.
4. Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: Risk factors, diagnosis, management, and the cardiovascular impact on the offspring. J Clin Med. 2019;8(10):1–22.
5. Triche EW, Harland KK, Field EH, Rubenstein LM, Saftlas AF. Maternal-fetal HLA sharing and preeclampsia: Variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa. J Reprod Immunol [Internet]. 2014;101–102(1):111–9. Available from: http://dx.doi.org/10.1016/j.jri.2013.06.004
6. Tyas BD, Lestari P, Aldika Akbar MI. Maternal Perinatal Outcomes Related to Advanced Maternal Age in Preeclampsia Pregnant Women. J Fam Reprod Heal. 2019 Dec;13(4):191–200.
7. Subtil SFC, Mendes JMB, Areia ALF de A, Moura JPAS. Update on Thrombocytopenia in Pregnancy. Rev Bras Ginecol e Obstet Rev da Fed Bras das Soc Ginecol e Obstet. 2020 Dec;42(12):834–40.
8. Habas E, Rayani A, Ganterie R. Thrombocytopenia in hypertensive disease of pregnancy. J Obstet Gynecol India. 2013;63(2):96–100.
9. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Oct;76(14):1690–702.
10. Rafida M, Mochtar NM, Artiningtyas ND, Anas M. Relationship of Age, Body Mass Index, and Gravida in Pregnant Women With Preeclampsia in Muhammadiyah Hospital Surabaya. Proc 4th Int Conf Sustain Innov 2020–Health Sci Nurs (ICoSIHSN 2020). 2021;33(ICoSIHSN 2020):37–42.
11. Miller EC, Wilczek A, Bello NA, Tom S, Wapner R, Suh Y. Pregnancy, preeclampsia and maternal aging: From epidemiology to functional genomics. Ageing Res Rev. 2022 Jan;73:101535.
12. Barbot M, Ceccato F, Scaroni C. The pathophysiology and treatment of hypertension in patients with Cushing’s syndrome. Front Endocrinol (Lausanne). 2019;10(MAY):1–9.
13. Arwan B, Sriyanti R. Relationship between Gravida Status , Age , BMI ( Body Mass Index ) and Preeclampsia. Andalas Obstet Gynecol J. 2020;4(1):13–21.
14. Reese JA, Peck JD, Deschamps DR, McIntosh JJ, Knudtson EJ, Terrell DR, et al. Platelet Counts during Pregnancy. N Engl J Med. 2018;379(1):32–43.
15. Thalor N, Singh K, Pujani M, Chauhan V, Agarwal C, Ahuja R. A correlation between platelet indices and preeclampsia. Hematol Transfus cell Ther. 2019;41(2):129–33.
16. Dadhich S, Agrawal S, Soni M, Choudhary R, Jain R, Sharma S, et al. Predictive value of platelet indices in development of preeclampsia. J SAFOG. 2012;4(1):17–21.
17. Sachan R, Patel ML, Vandana, Sachan P, Shyam R. Role of platelet count and mean platelet volume and red cell distribution width in the prediction of preeclampsia in early pregnancy. J Fam Med Prim care. 2021 Feb;10(2):838–43.
18. Melchiorre K, Giorgione V, Thilaganathan B. The placenta and preeclampsia: villain or victim? Am J Obstet Gynecol. 2022 Feb;226(2S):S954–62.
19. Helmo FR, Lopes AMM, Carneiro ACDM, Campos CG, Silva PB, Dos Reis Monteiro MLG, et al. Angiogenic and antiangiogenic factors in preeclampsia. Pathol Res Pract. 2018 Jan;214(1):7–14.
20. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007 Jan;100(1):88–95.
21. Vázquez-Rodríguez JG, Sánchez-Brito LO. Severity of preeclampsia: data from a high specialty hospital in Mexico City. Rev Med Inst Mex Seguro Soc. 2020;58(4):444–9.